<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718951</url>
  </required_header>
  <id_info>
    <org_study_id>CREC/769/09</org_study_id>
    <nct_id>NCT01718951</nct_id>
  </id_info>
  <brief_title>Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial</brief_title>
  <official_title>Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <authority>Hong Kong: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of golimumab with pamidronate in the treatment of axial
      spondyloarthropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of golimumab with pamidronate in the treatment of non-radiological
      axial spondyloarthropathy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response response</measure>
    <time_frame>week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients who achieve the Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI spinal inflammation scores</measure>
    <time_frame>week 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in MRI spinal inflammation scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spondyloarthropathy</condition>
  <arm_group>
    <arm_group_label>golimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>golimumab 50mg subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pamidronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pamidronate (60mg) intravenously every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>golimumab</intervention_name>
    <description>golimumab</description>
    <arm_group_label>golimumab</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>pamidronate</description>
    <arm_group_label>pamidronate</arm_group_label>
    <other_name>Aridia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects greater than 18 years of age

          2. Fulfilling the latest classification criteria for axial spondyloarthropathy

          3. Active spondylitis as defined by a Bath Ankylosing Spondylitis Disease Activity Index
             (BASDAI) score of more than 4 despite treatment with non-steroid anti-inflammatory
             drugs for more than 3 months

        Exclusion Criteria:

          1. Major surgery (including joint surgery) within 8 weeks prior to study entry

          2. History of treatment with anti-tumor necrosis factor agents or any investigational
             therapies within 12 months of study entry

          3. Immunization with a live/attenuated vaccine within 4 weeks prior to study entry

          4. Active current bacterial, viral, fungal, mycobacterial or other infections at study
             entry

          5. Chronic hepatitis B or hepatitis C carriers

          6. History of malignancies, including solid tumors and hemic malignancies

          7. History of congestive heart failure

          8. History of demyelinating disorders

          9. History of peripheral neuropathy

         10. Pregnant women or lactating mothers

         11. Baseline liver parenchymal enzymes elevated to more than 2 times normal

         12. Absolute lymphocyte count less than 500/mm3

         13. Serum creatinine level of more than 200umol/L
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>spondyloarthropathy</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylarthropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pamidronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
